rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AVBP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Guggenheim lowers ArriVent BioPharma stock price target to $28
      Nov 16Investing.comAVBP
      ArriVent BioPharma: ARR-217 Gives Us A Reason To Reconsider Our Strong Sell (Rating Upgrade)
      Nov 15Seeking AlphaAVBP
      Truist raises ArriVent BioPharma stock price target on drug data
      Oct 27Investing.comAVBP
      ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
      Oct 27Yahoo FinanceAVBP
      ArriVent BioPharma (AVBP) Advances ARR 217 Into Phase 1b, Is The Selloff Overdone?
      Oct 27Yahoo FinanceAVBP
      ArriVent reports phase 1 data for cancer drug ARR-217
      Oct 25Investing.comAVBP
      Why ArriVent BioPharma Stock Is In Focus After Trial Failure And Legal Probe
      Oct 24Yahoo FinanceAVBP
      ArriVent to present phase 1 data for ARR-217 at ESMO
      Oct 23Investing.comAVBP
      ArriVent doses first patient in ARR-002 ovarian cancer trial
      Oct 12Investing.comAVBP
      ArriVent BioPharma Doses First Patient in Phase 1 Trial of ARR-002 for Ovarian, Endometrial Cancer
      Oct 12Yahoo FinanceAVBP
      H.C. Wainwright cuts ArriVent BioPharma price target to $27 on trial miss
      Oct 8Investing.comAVBP
      Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)

      Detailed price information for Arrivent Biopharma Inc (AVBP-Q) from The Globe and Mail including charting and trades.

      Oct 8The Globe and MailAVBP
      Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails
      Oct 8Yahoo FinanceAVBP
      Why is Shanghai Allist Pharmaceuticals stock crashing today?
      Oct 8Investing.comAVBP
      AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
      Oct 7MorningstarAVBP
      ArriVent’s stock plummets on Phase III NSCLC trial failure
      Oct 7Yahoo FinanceAVBP
      BTIG cuts ArriVent BioPharma stock price target on trial results
      Oct 7Investing.comAVBP
      ArriVent’s Failed Trial Deals Blow to China-Origin Cancer Drug
      Oct 7BloombergAVBP
      Chinese biotech faces reality check as ArriVent drug failure sinks stock in US

      US-listed ArriVent lost nearly half its value after a Chinese-licensed cancer drug failed a late-stage trial.

      Oct 7South China Morning PostAVBP
      Avbp stock hits 52-week low at 12.09 USD
      Oct 7Investing.comAVBP
      ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
      Oct 6MorningstarAVBP
      ArriVent BioPharma: Phase 3 Failure Resets The Investment Case (Rating Downgrade)
      Oct 6Seeking AlphaAVBP
      Why Is ArriVent BioPharma Stock Tumbling Today? - ArriVent BioPharma (NASDAQ:AVBP)

      ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.

      Oct 6BenzingaAVBP
      ArriVent collapses on disappointing lung cancer data
      Oct 6Yahoo FinanceAVBP
      Why This Biotech Stock Is Having Its Worst Day Ever
      Oct 6Barron'sAVBP
      ArriVent’s lung cancer drug trial misses primary endpoint
      Oct 6Investing.comAVBP
      ArriVent stock plunges on cancer trial failure (AVBP:NASDAQ)

      ArriVent BioPharma (AVBP) stock plunges 50% as lead asset fails in a late-stage trial for a type of lung cancer. Read more here.

      Oct 6Seeking AlphaAVBP
      Why is Arrivent Biopharma stock collapsing today?
      Oct 6Investing.comAVBP
      ArriVent stock tumbles 60% after trial misses primary endpoint
      Oct 6Investing.comAVBP
      ArriVent's lung cancer treatment fails late-stage trial
      Oct 6Yahoo FinanceAVBP
      ArriVent's cancer pill fails to 'meaningfully' delay disease progression, shares dive
      Oct 6ReutersAVBP
      ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low

      ArriVent BioPharma Inc. (NASDAQ:AVBP) stock fell on Tuesday with a session volume of 14.10 million compared to the average volume of 524.163 thousand, according to Benzinga Pro data. The company announced that its Phase 3 FURVENT trial evaluating firmonertinib failed to achieve its primary endpoint. The clinical-stage biopharmaceutical company tested the drug as a standalone therapy for patients suffering from previously untreated, locally advanced, or metastatic non-squamous non-small cell lung

      Oct 6Yahoo FinanceAVBP
      Cantor Fitzgerald reiterates Overweight on ArriVent stock
      Sep 22Investing.comAVBP
      Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner
      Sep 9MorningstarAVBP
      ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case (NASDAQ:AVBP)
      Aug 27Seeking AlphaAVBP

      This is the newest page. Registered accounts read further back.